Kenneth S. Cohen to Middle Aged
This is a "connection" page, showing publications Kenneth S. Cohen has written about Middle Aged.
Connection Strength
0.287
-
Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) managed with delayed therapeutic plasma exchange (TPE). J Clin Apher. 2022 Feb; 37(1):117-121.
Score: 0.051
-
Circulating CD31+ leukocyte frequency is associated with cardiovascular risk factors. Atherosclerosis. 2013 Jul; 229(1):228-33.
Score: 0.029
-
Circulating CD34(+) progenitor cell frequency is associated with clinical and genetic factors. Blood. 2013 Feb 21; 121(8):e50-6.
Score: 0.028
-
Visante OCT measurement of central corneal thickness following Descemet's stripping endothelial keratoplasty. Ophthalmic Surg Lasers Imaging. 2010 Dec 01; 41 Online:e1-3.
Score: 0.024
-
Visante™ OCT measurement of central corneal thickness following Descemet's stripping endothelial keratoplasty. Ophthalmic Surg Lasers Imaging. 2010 Dec 01; 41 Online:e1-3.
Score: 0.024
-
Retinal thickness measurement after phacoemulsification. J Cataract Refract Surg. 2004 Jul; 30(7):1501-6.
Score: 0.015
-
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. N Engl J Med. 2022 08 18; 387(7):599-610.
Score: 0.014
-
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
Score: 0.011
-
Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. Neuro Oncol. 2017 Oct 19; 19(11):1542-1552.
Score: 0.010
-
University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL. Br J Haematol. 2018 04; 181(2):264-267.
Score: 0.009
-
Identifying early dropouts from a rehabilitation program for psychiatric outpatients. Psychiatr Serv. 1995 Oct; 46(10):1076-8.
Score: 0.008
-
Disseminated oligodendroglial-like leptomeningeal tumor of childhood: a distinctive clinicopathologic entity. Acta Neuropathol. 2012 Nov; 124(5):627-41.
Score: 0.007
-
Circulating angiogenic cell populations, vascular function, and arterial stiffness. Atherosclerosis. 2012 Jan; 220(1):145-50.
Score: 0.006
-
Genetic and clinical correlates of early-outgrowth colony-forming units. Circ Cardiovasc Genet. 2011 Jun; 4(3):296-304.
Score: 0.006
-
T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse. Leuk Lymphoma. 2011 Feb; 52(2):214-22.
Score: 0.006
-
Association of colony-forming units with coronary artery and abdominal aortic calcification. Circulation. 2010 Sep 21; 122(12):1176-82.
Score: 0.006
-
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10; 28(17):2817-23.
Score: 0.006
-
Sixteen-year predictors of substance use disorder diagnoses for patients with mental health disorders. Subst Abus. 2009 Jan-Mar; 30(1):40-6.
Score: 0.005
-
Determining factors for corneal endothelial cell loss by using bimanual microincision phacoemulsification and power modulation. Cornea. 2007 Oct; 26(9):1049-55.
Score: 0.005
-
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nat Clin Pract Oncol. 2007 May; 4(5):316-21.
Score: 0.005
-
Quantification of macular and optic disc hyperfluorescence after phacoemulsification in diabetes mellitus. J Cataract Refract Surg. 2006 May; 32(5):803-11.
Score: 0.004
-
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol. 2005 Nov 01; 23(31):8136-9.
Score: 0.004
-
No responses to oral etoposide in 15 patients with recurrent brain tumors. Med Pediatr Oncol. 2000 Jul; 35(1):80-2.
Score: 0.003